Coronary Artery Disease Clinical Trial
— HYBRIDOfficial title:
A Randomized Controlled Trial to Investigate the Ideal Sequence of Hybrid Coronary Revascularization With Endoscopic Coronary Revascularization
Hybrid coronary revascularization (HCR), a combination of coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI), has emerged as an alternative treatment for multivessel coronary artery disease patients. However, the ideal sequence (PCI or CABG) is unclear. The overall aim of this study is to investigate the best sequence within hybrid coronary revascularization using endoscopic coronary bypass grafting (i.e., first CABG then PCI versus first PCI then CABG)
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Multivessel coronary disease, defined as = 50% diameter stenosis by visual estimation in 2 or more of the three major epicardial vessels or major side branches, with at least one or more one stenosis amenable to revascularization with PCI, if the patient cannot be full revascularized by surgery for a specific reason as determined by the Heart Team. Patients with a non-dominant right coronary artery may be included if the left anterior descending artery (LAD) and left circumflex have =50% stenosis. - Age 18-85 - Willing and able to provide informed, written consent Exclusion Criteria: - Requirement for other cardiac or non-cardiac surgical procedures (e.g., valve replacement, carotid revascularization) - Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support at the time of randomisation - Left main coronary artery disease - Contraindication for dual antiplatelet therapy - ST-Elevation Myocardial Infarction (STEMI) - Previous cardiac surgery - Participation in other interventional clinical trials - Recent coronary intervention (PCI) - Ongoing high risk non-ST-segment elevation acute coronary syndrome (ACS) - Life expectancy < 1 year - Active bleeding more or equal to BARC 2 at time of randomisation - Requiring renal replacement therapy - Undergoing evaluation for organ transplantation |
Country | Name | City | State |
---|---|---|---|
Belgium | Jessa Hospital | Hasselt | Limburg |
Lead Sponsor | Collaborator |
---|---|
Jessa Hospital |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 30-day net adverse clinical event (NACE) | NACE consists of major adverse cardiac and cerebrovascular events (MACCE) and major bleeding unrelated to CABG (Bleeding Academic Research Consortium (BARC) type 3 and 5) MACCE consists of: Death from any cause Myocardial infarction Stroke Target lesion revascularisation |
From the first procedure until 30 days after the second procedure. | |
Secondary | Key secondary outcome: 30-day major adverse cardiac and cerebrovascular events (MACCE) | MACCE consists of: Death from any cause Myocardial infarction Stroke Target lesion revascularisation |
From the first procedure until 30 days after the second procedure | |
Secondary | Key secondary outcome: 30-day major or clinically relevant non-major bleeding (BARC type 2, 3, 4, 5) | Major or clinically relevant non-major bleeding is assessed using BARC type 2, 3, 4, and 5. | From the first procedure until 30 days after the second procedure | |
Secondary | Key secondary outcome: One-year net adverse clinical event (NACE) | NACE consists of major adverse cardiac and cerebrovascular events (MACCE) and major bleeding unrelated to CABG (Bleeding Academic Research Consortium (BARC) type 3 and 5) MACCE consists of: Death from any cause Myocardial infarction Stroke Target lesion revascularisation |
From the first procedure until one year after the second procedure | |
Secondary | Key secondary outcome: one-year major adverse cardiac and cerebrovascular events (MACCE) | MACCE consists of: Death from any cause Myocardial infarction Stroke Target lesion revascularisation |
From the first procedure until one year after the second procedure | |
Secondary | Key secondary outcome: One-year major or clinically relevant non-major bleeding (BARC type 2, 3, 4, 5) | Major or clinically relevant non-major bleeding is assessed using BARC type 2, 3, 4, and 5. | From the first procedure until one year after the second procedure | |
Secondary | Mortality | Both all-cause mortality as the subdivision in cardiovascular death, noncardiovascular death and undetermined cause of death are examined. | From the first procedure until one year after the second procedure | |
Secondary | Myocardial infarction | Mycardial infarction is subdivided into: Periprocedural Spontaneous |
From the first procedure until one year after the second procedure | |
Secondary | Stent thrombosis | Stent thrombosis is subdivided into: Definite stent thrombosis Probable stent thrombosis Possible stent thrombosis |
From the first procedure until one year after the second procedure | |
Secondary | Stroke | Stroke is subdivided into: Ischemic stroke Hemorrhagic stroke Non-specified stroke |
From the first procedure until one year after the second procedure | |
Secondary | Revascularization | Revascularization is subdivided into: Target lesion revascularization (TLR) Target vessel revascularization (TVR) |
From the first procedure until one year after the second procedure | |
Secondary | Graft failure | Graft failure describes total graft occlusion that prevents blood flow through the graft to the revascularized part of the heart. | From the first procedure until one year after the second procedure | |
Secondary | Bleeding | Bleeding is assessed using the Bleeding Academic Research Consortium (BARC) classification, Thrombolysis In Myocardial Infarction (TIMI) bleeding classification and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO). classification BARC is subdivided into type zero (no bleeding) until five (probable/definite fatal bleeding), while the TIMI classification is divided into minimal, minor, and major. Gusto is subdivided into mild, moderate, and severe. |
From the first procedure until one year after the second procedure | |
Secondary | Quality of Life (QoL) using the Short-form 36 (SF-36) questionnaire | QoL will be questioned with the Short-form 36 (SF-36) questionnaire.SF-36 scores range from 0 (worst) to 100 (best). | 14, 30, 90, 180 and 365 days after the second procedure | |
Secondary | Quality of Life (QoL) using the Euro Quality of Life 5 dimensions (EQ-5D) questionnaire | The Euro Quality of Life 5 dimensions (EQ-5D) questionnaire will be used to assess Quality of Life. Questions of the descriptive system are scored from one (no problem to perform activity) to five (severe problem/unable to perform activity). The scores are combined in order to calculate an index value (ranging from 0-1) that reflects the health state with one being the best health state. Moreover, the visual analogue scale ranges from 0 to 100 with 0 representing the worst health state and 100 the best health state. | 14, 30, 90, 180 and 365 days after the second procedure | |
Secondary | Quality of Life (QoL) using the Seattle Angina Questionnaire short-form (SAQ-7) | QoL will be questioned with the Seattle Angina Questionnaire short-form (SAQ-7). The overall summary score ranges from 0 to 100 where higher ratings indicate a better health state. | 14, 30, 90, 180 and 365 days after the second procedure | |
Secondary | Quality of Life (QoL) using the Rose Dyspnea Scale (RDS) | The Rose Dyspnea Scale (RDS) will be used to assess Quality of Life. RDS is scored between zero and four. Zero corresponds to no dyspnea with activity and four to dyspnea that severly limits activity. | 14, 30, 90, 180 and 365 days after the second procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Coronary De Novo Lesions
|
N/A |